Bulk Manufacturer of Controlled Substances Application: Nanosyn Inc., 60653 [2021-23982]

Download as PDF 60653 Federal Register / Vol. 86, No. 210 / Wednesday, November 3, 2021 / Notices Appendix 3; or (ii) by U.S. government employees and contract personnel solely for cybersecurity purposes. The Commission will not otherwise disclose any confidential business information in a manner that would reveal the operations of the firm supplying the information. Summaries of Written Submissions: The Commission intends to publish summaries of the positions of interested persons in this report. If you wish to have a summary of your position included in an appendix to the report, please include a summary with your written submission and mark the summary as submitted for that purpose. The summary may not exceed 500 words, should be in MSWord format or a format that can be easily converted to MSWord, and should not include any confidential business information. The summary will be published as provided if it meets these requirements and is germane to the subject matter of the investigation. In the report the Commission will identify the name of the organization furnishing the summary and will include a link to the Commission’s Electronic Document Information System (EDIS) where the full written submission can be found. By order of the Commission. Issued: October 28, 2021. Lisa Barton, Secretary to the Commission. In accordance with 21 CFR 1301.33(a), this is notice that on September 23, 2021, Nanosyn Inc., 3331 Industrial Drive, Suite B, Santa Rosa, California 95403– 2062, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s): SUPPLEMENTARY INFORMATION: Drug code Controlled substance Oxymorphone ................. Fentanyl .......................... I 9652 9801 Schedule II III The company is a contract manufacturer. At the request of the company’s customers, it manufactures derivatives of the above controlled substances in bulk form. No other activities for these drug codes are authorized for this registration. Brian S. Besser, Acting Assistant Administrator. [FR Doc. 2021–23982 Filed 11–2–21; 8:45 am] BILLING CODE P DEPARTMENT OF JUSTICE Drug Enforcement Administration [FR Doc. 2021–23913 Filed 11–2–21; 8:45 am] BILLING CODE 7020–02–P [Docket No. DEA–920] DEPARTMENT OF JUSTICE Importer of Controlled Substances Application: Fisher Clinical Services, Inc. Drug Enforcement Administration AGENCY: Drug Enforcement Administration, Justice. ACTION: Notice of application. [Docket No. DEA–921] Bulk Manufacturer of Controlled Substances Application: Nanosyn Inc. Drug Enforcement Administration, Justice. ACTION: Notice of application. AGENCY: Nanosyn Inc. has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to SUPPLEMENTAL INFORMATION listed below for further drug information. DATES: Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before January 3, 2022. Such persons may also file a written request for a hearing on the application on or before January 3, 2022. SUMMARY: khammond on DSKJM1Z7X2PROD with NOTICES Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. ADDRESSES: VerDate Sep<11>2014 17:01 Nov 02, 2021 Jkt 256001 PO 00000 Frm 00041 Fmt 4703 Sfmt 4703 Controlled substance Marihuana Extract ..................... Psilocybin .................................. Methylphenidate ........................ Levorphanol .............................. Noroxymorphone ...................... Tapentadol ................................ Drug code Schedule 7350 7437 1724 9220 9668 9780 I I II II II II The company plans to import the listed controlled substances for clinical trials only. No other activity for these drug codes is authorized for this registration. Approval of permit applications will occur only when the registrant’s business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of Food and Drug Administration-approved or nonapproved finished dosage forms for commercial sale. Brian S. Besser, Acting Assistant Administrator. [FR Doc. 2021–23897 Filed 11–2–21; 8:45 am] Fisher Clinical Services, Inc. has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to SUPPLEMENTARY INFORMATION listed below for further drug information. DATES: Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before December 3, 2021. Such persons may also file a written request for a hearing on the application on or before December 3, 2021. ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing must SUMMARY: be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this is notice that on August 25, 2021, Fisher Clinical Services, Inc., 7554 Schantz Road, Allentown, Pennsylvania 18106– 9032, applied to be registered as an importer of the following basic class(es) of controlled substance(s): BILLING CODE P DEPARTMENT OF JUSTICE Drug Enforcement Administration [Docket No. DEA–918] Bulk Manufacturer of Controlled Substances Application: Groff Global Drug Enforcement Administration, Justice. ACTION: Notice of application. AGENCY: Groff Global has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to SUPPLEMENTARY INFORMATION listed below for further drug information. SUMMARY: E:\FR\FM\03NON1.SGM 03NON1

Agencies

[Federal Register Volume 86, Number 210 (Wednesday, November 3, 2021)]
[Notices]
[Page 60653]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-23982]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-921]


Bulk Manufacturer of Controlled Substances Application: Nanosyn 
Inc.

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

-----------------------------------------------------------------------

SUMMARY: Nanosyn Inc. has applied to be registered as a bulk 
manufacturer of basic class(es) of controlled substance(s). Refer to 
Supplemental Information listed below for further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), 
and applicants therefore, may file written comments on or objections to 
the issuance of the proposed registration on or before January 3, 2022. 
Such persons may also file a written request for a hearing on the 
application on or before January 3, 2022.

ADDRESSES: Written comments should be sent to: Drug Enforcement 
Administration, Attention: DEA Federal Register Representative/DPW, 
8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this 
is notice that on September 23, 2021, Nanosyn Inc., 3331 Industrial 
Drive, Suite B, Santa Rosa, California 95403-2062, applied to be 
registered as a bulk manufacturer of the following basic class(es) of 
controlled substance(s):

------------------------------------------------------------------------
                                          Drug
          Controlled substance            code           Schedule
------------------------------------------------------------------------
Oxymorphone............................    9652  II
Fentanyl...............................    9801  II
------------------------------------------------------------------------

    The company is a contract manufacturer. At the request of the 
company's customers, it manufactures derivatives of the above 
controlled substances in bulk form. No other activities for these drug 
codes are authorized for this registration.

Brian S. Besser,
Acting Assistant Administrator.
[FR Doc. 2021-23982 Filed 11-2-21; 8:45 am]
BILLING CODE P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.